Beta-casein A2 Composition for Blood Glucose Regulation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Consumption of beta-casein A1 in milk and milk products is linked to elevated blood glucose levels and insulin resistance, contributing to health issues like diabetes and metabolic syndrome, while beta-casein A2 has shown potential in regulating glucose levels and improving insulin sensitivity.
Innovation Solution
A composition containing 100% beta-casein A2, exclusively sourced from milk or milk products, eliminating beta-casein A1 to reduce symptoms of hyperglycemia by promoting insulin receptor and substrate gene expression, thereby managing glucose homeostasis and lowering the risk of type II diabetes.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If beta-casein A1 is consumed in milk and milk products, then protein intake is provided, but blood glucose levels increase and insulin resistance develops
Solution Approach 1:
The patent extracts and eliminates beta-casein A1 from milk products while retaining beta-casein A2. This selective removal resolves the contradiction by providing protein benefits from casein while eliminating the harmful effect of elevated blood glucose and insulin resistance associated with beta-casein A1 consumption.
Solution Approach 2:
The patent applies local quality by creating milk products with a specific protein composition - predominantly beta-casein A2 variant. This localized modification of protein quality allows the product to provide nutritional benefits while avoiding the harmful metabolic effects associated with beta-casein A1.
2Quantity of substance
If conventional milk containing beta-casein A1 is used, then general protein nutrition is provided, but hyperglycemia symptoms worsen
Solution Approach 1:
The patent changes the amino acid parameter at position 67 of beta-casein from histidine (A1 variant) to proline (A2 variant). This parameter change fundamentally alters the digestion products formed, eliminating beta-casomorphin-7 production and thereby preventing the harmful hyperglycemic effects while maintaining protein nutrition.
3Reliability
If beta-casein A1 is present in milk products, then casein protein benefits are provided, but diabetes risk increases
Solution Approach 1:
The patent selectively removes beta-casein A1 from the milk product composition while preserving beta-casein A2. This extraction eliminates the diabetogenic risk associated with beta-casein A1 consumption while maintaining the beneficial nutritional and functional properties of casein protein.
Solution Approach 2:
The patent creates a composite protein structure in milk products dominated by beta-casein A2 variant (at least 70%, preferably at least 90%). This composite approach ensures the product delivers reliable casein protein benefits while the specific composition profile prevents diabetes risk development.
Data Source
Figure 1~2
Figure 3
Figure 4
AI summary
Regulating the level of glucose in the blood of an animal comprising the consumption by the animal of a composition containing beta-casein, or providing the composition to the animal for consumption, where the beta-casein comprises at least 75% by weight beta-casein A2. Uses include managing the symptoms of hyperglycaemia and associated conditions including diabetes. The effect is both acute (post-exposure to the composition) and ongoing.